Camelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.
UAB Nemuno vaistinė, operating under the brand name Camelia, is the leading pharmacy chain in Lithuania. The group carries out retail and wholesale trade in pharmaceuticals, food supplements, medical devices and cosmetics. Camelia’s pharmacy chain includes a countrywide network of approximately 300 own and 30 franchise outlets and manages one of the leading online pharmacies in Lithuania. Besides pharmacy retail and wholesale, the group is also involved in the development of pharmaceutical and nutraceutical products under its own brand names (private label).
Medigate Management UAB is a private investment holding company owned by Mr. Petras Bartkus (a minority shareholder in Camelia before the transaction). Medigate Management owns UAB Medigate, a developer and wholesaler of food supplements, medical devices and cosmetics in Lithuania.
CGP Management UAB is a private holding company owned by the founder of the Camelia pharmacy chain.
Oaklins’ team in Lithuania acted as the sole financial advisor to CGP Management on the sale of the Camelia pharmacy chain to Medigate Management.
Falar com a equipa da transação
Transações relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Saber maisbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Saber maisBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Saber mais